Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.
Saved in:
| Title: | Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. |
|---|---|
| Authors: | Asselah T; Department of Hepatology, Hôpital Beaujon, Université de Paris-Cité, INSERM UMR1149, Clichy, France., Lampertico P; Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; CRC 'A. M. And A. Migliavacca' Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy., Aleman S; Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden., Bourlière M; Hôpital Saint Joseph, Marseille, France., Streinu-Cercel A; National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania.; Carol Davila Medicine and Pharmacy University, Bucharest, Romania., Bogomolov P; M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation., Morozov V; LLC Medical Company 'Hepatolog', Samara, Russian Federation., Stepanova T; Limited Liability Company 'Clinic of Modern Medicine', Moscow, Russian Federation., Lazar S; Dr. Victor Babes Foundation, Bucharest, Romania., Manuilov D; Gilead Sciences Inc., Foster City, California, USA., Mercier RC; Gilead Sciences Inc., Foster City, California, USA., Tseng S; Gilead Sciences Inc., Foster City, California, USA., Ye L; Gilead Sciences Inc., Foster City, California, USA., Flaherty JF; Gilead Sciences Inc., Foster City, California, USA., Osinusi A; Gilead Sciences Inc., Foster City, California, USA., Da BL; Gilead Sciences Inc., Foster City, California, USA., Chee GM; Gilead Sciences Inc., Foster City, California, USA., Lau AH; Gilead Sciences Inc., Foster City, California, USA., Brunetto MR; Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy.; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Wedemeyer H; Clinic for Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany. |
| Source: | Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2025 Apr; Vol. 45 (4), pp. e16174. Date of Electronic Publication: 2024 Dec 08. |
| Publication Type: | Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39648559 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Asselah+T%22">Asselah T</searchLink>; Department of Hepatology, Hôpital Beaujon, Université de Paris-Cité, INSERM UMR1149, Clichy, France.<br /><searchLink fieldCode="AU" term="%22Lampertico+P%22">Lampertico P</searchLink>; Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; CRC 'A. M. And A. Migliavacca' Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Aleman+S%22">Aleman S</searchLink>; Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Bourlière+M%22">Bourlière M</searchLink>; Hôpital Saint Joseph, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Streinu-Cercel+A%22">Streinu-Cercel A</searchLink>; National Institute for Infectious Diseases 'Prof. Dr. Matei Bals', Bucharest, Romania.; Carol Davila Medicine and Pharmacy University, Bucharest, Romania.<br /><searchLink fieldCode="AU" term="%22Bogomolov+P%22">Bogomolov P</searchLink>; M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation.<br /><searchLink fieldCode="AU" term="%22Morozov+V%22">Morozov V</searchLink>; LLC Medical Company 'Hepatolog', Samara, Russian Federation.<br /><searchLink fieldCode="AU" term="%22Stepanova+T%22">Stepanova T</searchLink>; Limited Liability Company 'Clinic of Modern Medicine', Moscow, Russian Federation.<br /><searchLink fieldCode="AU" term="%22Lazar+S%22">Lazar S</searchLink>; Dr. Victor Babes Foundation, Bucharest, Romania.<br /><searchLink fieldCode="AU" term="%22Manuilov+D%22">Manuilov D</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Mercier+RC%22">Mercier RC</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Tseng+S%22">Tseng S</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Ye+L%22">Ye L</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Flaherty+JF%22">Flaherty JF</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Osinusi+A%22">Osinusi A</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Da+BL%22">Da BL</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Chee+GM%22">Chee GM</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Lau+AH%22">Lau AH</searchLink>; Gilead Sciences Inc., Foster City, California, USA.<br /><searchLink fieldCode="AU" term="%22Brunetto+MR%22">Brunetto MR</searchLink>; Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy.; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.<br /><searchLink fieldCode="AU" term="%22Wedemeyer+H%22">Wedemeyer H</searchLink>; Clinic for Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101160857%22">Liver international : official journal of the International Association for the Study of the Liver</searchLink> [Liver Int] 2025 Apr; Vol. 45 (4), pp. e16174. <i>Date of Electronic Publication: </i>2024 Dec 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101160857 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1478-3231 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214783223%22">14783223 </searchLink><i>NLM ISO Abbreviation: </i>Liver Int <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39648559 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/liv.16174 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e16174 Titles: – TitleFull: Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Asselah T – PersonEntity: Name: NameFull: Lampertico P – PersonEntity: Name: NameFull: Aleman S – PersonEntity: Name: NameFull: Bourlière M – PersonEntity: Name: NameFull: Streinu-Cercel A – PersonEntity: Name: NameFull: Bogomolov P – PersonEntity: Name: NameFull: Morozov V – PersonEntity: Name: NameFull: Stepanova T – PersonEntity: Name: NameFull: Lazar S – PersonEntity: Name: NameFull: Manuilov D – PersonEntity: Name: NameFull: Mercier RC – PersonEntity: Name: NameFull: Tseng S – PersonEntity: Name: NameFull: Ye L – PersonEntity: Name: NameFull: Flaherty JF – PersonEntity: Name: NameFull: Osinusi A – PersonEntity: Name: NameFull: Da BL – PersonEntity: Name: NameFull: Chee GM – PersonEntity: Name: NameFull: Lau AH – PersonEntity: Name: NameFull: Brunetto MR – PersonEntity: Name: NameFull: Wedemeyer H IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2025 Apr Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1478-3231 Numbering: – Type: volume Value: 45 – Type: issue Value: 4 Titles: – TitleFull: Liver international : official journal of the International Association for the Study of the Liver Type: main |
| ResultId | 1 |
